论文部分内容阅读
一九六○年Linder观察到心可宁(Pronylamine是一种新的冠脉扩张剂)在犬心肺标本中抑制心脏功能。不久,Haas等记录到异博停(Verapamil,扩张冠脉药)在离体猫和兔的心肌标本上具有负性心肌收缩效应。这些药的作用显然同那些古典的平滑肌松弛剂如硝酸甘油、罂粟硷等不同,后者只有在高浓度下才抑制心肌。开始时把这些新药看做是肾上腺素能阻断药。一九七一年,Fleckehstein首先提出,这类药物的作用可
In 1960, Linder observed that cinnadon (Pronylamine is a new coronary dilating agent) inhibits cardiac function in canine cardiopulmonary specimens. Soon, Haas et al. Documented that Verapamil (dilated coronary drug) had a negative myocardial contractile effect on isolated myocardial specimens of cats and rabbits. The role of these drugs is clearly different from those of classical smooth muscle relaxants such as nitroglycerin, papaverine and the like, which inhibit myocardium only at high concentrations. Initially, these new drugs as adrenergic blocking drugs. In 1973, Fleckehstein first proposed the role of such drugs